Abstract:Introduction: Infantile Hemangioma (IH) is a prevalent benign vascular tumor affecting approximately 5-10% of infants. Its underlying pathogenesis remains enigmatic, and current therapeutic approaches show limited effectiveness. Our study aimed to discover potential IH-associated therapeutics through a transcriptomic, computational drug repurposing methodology. Methods: Utilizing the IH-specific dataset GSE127487 from the Gene Expression Omnibus, we identified differentially expressed genes (DEGs) and conducted weighted gene coexpression network analysis (WGCNA). Subsequently, a protein-protein interaction (PPI) network was constructed to obtain the top 100 hub genes. Drug candidates were sourced from the Connectivity Map (CMap) and Comparative Toxicogenomics Database (CTD). Results: Our analysis revealed 1203 DEGs and a significant module of 1780 mRNAs strongly correlated with IH. These genes were primarily enriched in the PI3K/AKT/MTOR, RAS/MAPK, and CGMP/PKG signaling pathway. After creating a PPI network of overlapping genes, we filtered out the top 100 hub genes. Ultimately, 44 non-toxic drugs were identified through the CMap and CTD databases. Twelve molecular-targeting agents (belinostat, chir 99021, dasatinib, entinostat, panobinostat, sirolimus, sorafenib, sunitinib, thalidomide, U 0126, vorinostat, and wortmannin) may be potential candidates for IH therapy. Moreover, in vitro experiments demonstrated that entinostat, sorafenib, dasatinib, and sirolimus restricted the proliferation and migration and initiated apoptosis in HemEC cells, thereby underscoring their potential therapeutic value. Conclusion: Our investigation revealed that the pathogenic mechanism underlying IH might be closely associated with the PI3K/AKT/MTOR, RAS/MAPK, and CGMP/PKG signaling pathways. Furthermore, we identified twelve molecular-targeting agents among the predicted drugs that show promise as therapeutic candidates for IH.

Immunohistochemical and ultrastructural identification of telocytes in the infantile hemangioma

Ultrastructural and immunohistochemical characteristics of telocytes in human scalp tissue

Tumor-associated telocytes

Biology of Infantile Hemangioma

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Cell Fate Regulation During the Development of Infantile Hemangioma

Telocytes in Liver: Electron Microscopic and Immunofluorescent Evidence

Cardiac Telocytes and Fibroblasts in Primary Culture: Different Morphologies and Immunophenotypes

The role of multipotential stem cells in human infantile hemangioma

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

Telocytes In Regenerative Medicine

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

Identifying Potential Diagnostic and Therapeutic Targets for Infantile Hemangioma Using WGCNA and Machine Learning Algorithms

A Common Polymorphism Within the IGF2 Imprinting Control Region is Associated with Parent of Origin Specific Effects in Infantile Hemangiomas.

Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.

Immunohistochemical characterization and functional identification of mammary gland telocytes in the self-assembly of reconstituted breast cancer tissue in vitro.

CENPF May Act as a Novel Marker and Highlight the Influence of Pericyte in Infantile Hemangioma

Signaling pathways in the development of infantile hemangioma

Mast cell in infantile hemangioma

Telocyte Morphologies and Potential Roles in Diseases